Manufacturers report positive results for faricimab hits for wet age-related macular degeneration

In two Phase III studies, this bispecific antibody (acts on Ang-2 and VEGF-A pathways) was non-inferior to aflibercept for visual acuity outcomes in people living with neovascular or wet age-related macular degeneration.

PharmaTimes